Summary:
Open-label Study to Assess Hospitalization Rates in Adult Schizophrenic Patients Treated With Oral Antipsychotics for 6 Months and IM Depot Aripiprazole for 6 Months, Respectively, in a Naturalistic Community Setting.
Qualification Requirements:
• Subjects who are able to provide written informed consent. If the IRB requires consent by a legally acceptable representative in addition to the subject, all required consents must be obtained prior to any protocol-required procedure.
• Male and female subjects 18 to 65 years of age, inclusive.
• Current diagnosis of schizophrenia as defined by DSM-IV-TR criteria and a history of the illness for at least 1 year (12 months).
• Subjects who in the investigator's judgment would benefit from extended treatment with a long-acting injectable formulation.
• Subjects who have at least 1 inpatient psychiatric hospitalization in the 2 years (24 months) prior to screening, but have been managed as outpatients for the 4 weeks prior entering the study.
• Subjects must have been on oral antipsychotic treatment for the full 7 months prior to the screening phase.
• Subjects who have shown response to previous antipsychotic treatment.
• Subjects who understand the nature of the trial and are able to follow the protocol requirements.
Qualified Participants May Receive:
Compensation, Free Physical, Free Assessments, Free ECGs